{"id":439741,"date":"2021-02-19T07:03:15","date_gmt":"2021-02-19T12:03:15","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=439741"},"modified":"2021-02-19T07:03:15","modified_gmt":"2021-02-19T12:03:15","slug":"decibel-therapeutics-to-present-at-the-44th-annual-association-for-research-in-otolaryngology-aro-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/decibel-therapeutics-to-present-at-the-44th-annual-association-for-research-in-otolaryngology-aro-conference\/","title":{"rendered":"Decibel Therapeutics to Present at the 44th Annual Association for Research in Otolaryngology (ARO) Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">BOSTON, Feb.  19, 2021  (GLOBE NEWSWIRE) &#8212; Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, announced today that it will present findings from its drug discovery and development programs at the 44<sup>th<\/sup> Annual MidWinter Meeting of the Association for Research in Otolaryngology (ARO), which will be held virtually February 20\u201324, 2021.<\/p>\n<p align=\"left\">The Decibel team will have a total of eight podium and poster presentations during this year\u2019s meeting. Several presentations will focus on DB-OTO, Decibel\u2019s investigational gene therapy being developed to restore hearing in children with a deficiency in the otoferlin gene, and DB-ATO, a regenerative gene therapy program designed to restore balance in patients with bilateral vestibulopathy, or BVP, by regenerating lost hair cells within the vestibule.<\/p>\n<p align=\"left\">\n        <em>Podium Presentations<\/em>\n      <\/p>\n<p align=\"left\">\n        <strong>Podium 18.3 | Promoter Control Optimizes AAV-ATOH1 Gene Therapy for Vestibular Hair Cell Regeneration<\/strong><br \/>\n        <br \/>Presenter: Tian Yang, Ph.D.<br \/>Session Title: Regeneration of Hair Cells &amp; Synapses<br \/>Date &amp; Time: Monday, February 22, 3:30\u20133:45 p.m. ET<\/p>\n<p align=\"left\">\n        <strong>Podium 25.2 | Development of an AAV-Based Gene Therapy for Children with Congenital Hearing Loss Due to Otoferlin Deficiency (DB-OTO)<\/strong><br \/>\n        <br \/>Presenter: Adam Palermo, Ph.D.<br \/>Session Title: Inner Ear Therapeutics<br \/>Date &amp; Time: Tuesday, February 23, 3:15\u20133:30 p.m. ET<\/p>\n<p align=\"left\">\n        <strong>Podium 25.3 | Mechanisms of Promoter-Driven AAV Toxicity in the Ear<\/strong><br \/>\n        <br \/>Presenter: Gabriela Pregernig, Ph.D.<br \/>Session Title: Inner Ear Therapeutics<br \/>Date &amp; Time: Tuesday, February 23, 3:30\u20133:45 p.m. ET<\/p>\n<p align=\"left\">\n        <strong>Podium 25.4 | Safely Delivering Adeno-Associated Viral Vectors to the Ear for Therapeutics<\/strong><br \/>\n        <br \/>Presenter: Peter Weber, MBA, M.D.<br \/>Session Title: Inner Ear Therapeutics<br \/>Date &amp; Time: Tuesday, February 23, 3:45\u20134:00 p.m. ET<\/p>\n<p align=\"left\">\n        <em>Poster Presentations<\/em>\n      <\/p>\n<p align=\"left\">\n        <strong>SU97 | Leveraging single cell genomics with tissue culture to identify and screen targets for vestibular regeneration<\/strong>\n      <\/p>\n<p align=\"left\">\n        <strong>M117 | Gentamicin-Induced Models of Vestibular Dysfunction in Mice for Evaluating Therapeutic Potential of Vestibular Hair Cell Regeneration<\/strong>\n      <\/p>\n<p align=\"left\">\n        <strong>T96 | Transcriptional comparison of AAV-Atoh1 and AAV-Atoh1\/Pou4f3\/Gfi1 regenerated hair cells in the neonatal mouse cochlea<\/strong>\n      <\/p>\n<p align=\"left\">\n        <strong>W78 | Inner Ear Tropism of Natural and Engineered AAV Serotypes in Non-Human Primate Enables Therapeutic Targeting of a Diverse Set of Cochlear Cell Types<\/strong>\n      <\/p>\n<p align=\"left\">\n        <strong>About Decibel Therapeutics<\/strong>\n      <\/p>\n<p align=\"left\">Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine. Decibel has built a proprietary platform that integrates single-cell genomics and bioinformatic analyses, precision gene therapy technologies and expertise in inner ear biology. Decibel is leveraging its platform to advance gene therapies designed to selectively replace genes for the treatment of congenital, monogenic hearing loss and to regenerate inner ear hair cells for the treatment of acquired hearing and balance disorders. Decibel\u2019s pipeline, including its lead gene therapy program, DB-OTO, to treat congenital, monogenic hearing loss, is designed to deliver on our vision of a world in which the privileges of hearing and balance are available to all.<\/p>\n<p align=\"left\">\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Julie Seidel<br \/>Stern Investor Relations, Inc.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YEpeWA8Fu4uB5Iwy1FcF63PpxJJyVhZsDVtZ6Ivh0EA426fDIR2rHLsgP4yHYEjtPNQ08vJdwIVXIOmoSJQf4Uv4RHjmInwzrUbeovCFiDk=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">julie.seidel@sternir.com<\/a><br \/>212-362-1200<\/p>\n<p align=\"left\">\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>Matthew Corcoran<br \/>Ten Bridge Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7dieGl6IBEhklvrMvRj4osJBykgkHApuE0dlV9cFrDOL9JaR5LucUZdTGh8idq2eFiMfjdpSu50gayAA8utomoOKC9idjazO3BTZsSNdi9sNu0hnkTO1MdSrrN_95TKUwxVp5WA0dEy6nIqtwXiUgw==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">mcorcoran@tenbridgecommunications.com<\/a><br \/>617-866-7350<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NjAzMCMzOTg0OTg5IzIyMDU3NTM=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/23d2a772-f3ce-48b3-8e93-c263c2a2d10d\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BOSTON, Feb. 19, 2021 (GLOBE NEWSWIRE) &#8212; Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, announced today that it will present findings from its drug discovery and development programs at the 44th Annual MidWinter Meeting of the Association for Research in Otolaryngology (ARO), which will be held virtually February 20\u201324, 2021. The Decibel team will have a total of eight podium and poster presentations during this year\u2019s meeting. Several presentations will focus on DB-OTO, Decibel\u2019s investigational gene therapy being developed to restore hearing in children with a deficiency in the otoferlin gene, and DB-ATO, a regenerative gene therapy program designed to restore balance in patients with &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/decibel-therapeutics-to-present-at-the-44th-annual-association-for-research-in-otolaryngology-aro-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Decibel Therapeutics to Present at the 44th Annual Association for Research in Otolaryngology (ARO) Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-439741","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Decibel Therapeutics to Present at the 44th Annual Association for Research in Otolaryngology (ARO) Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/decibel-therapeutics-to-present-at-the-44th-annual-association-for-research-in-otolaryngology-aro-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Decibel Therapeutics to Present at the 44th Annual Association for Research in Otolaryngology (ARO) Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BOSTON, Feb. 19, 2021 (GLOBE NEWSWIRE) &#8212; Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, announced today that it will present findings from its drug discovery and development programs at the 44th Annual MidWinter Meeting of the Association for Research in Otolaryngology (ARO), which will be held virtually February 20\u201324, 2021. The Decibel team will have a total of eight podium and poster presentations during this year\u2019s meeting. Several presentations will focus on DB-OTO, Decibel\u2019s investigational gene therapy being developed to restore hearing in children with a deficiency in the otoferlin gene, and DB-ATO, a regenerative gene therapy program designed to restore balance in patients with &hellip; Continue reading &quot;Decibel Therapeutics to Present at the 44th Annual Association for Research in Otolaryngology (ARO) Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/decibel-therapeutics-to-present-at-the-44th-annual-association-for-research-in-otolaryngology-aro-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-02-19T12:03:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NjAzMCMzOTg0OTg5IzIyMDU3NTM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/decibel-therapeutics-to-present-at-the-44th-annual-association-for-research-in-otolaryngology-aro-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/decibel-therapeutics-to-present-at-the-44th-annual-association-for-research-in-otolaryngology-aro-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Decibel Therapeutics to Present at the 44th Annual Association for Research in Otolaryngology (ARO) Conference\",\"datePublished\":\"2021-02-19T12:03:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/decibel-therapeutics-to-present-at-the-44th-annual-association-for-research-in-otolaryngology-aro-conference\\\/\"},\"wordCount\":503,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/decibel-therapeutics-to-present-at-the-44th-annual-association-for-research-in-otolaryngology-aro-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE1NjAzMCMzOTg0OTg5IzIyMDU3NTM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/decibel-therapeutics-to-present-at-the-44th-annual-association-for-research-in-otolaryngology-aro-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/decibel-therapeutics-to-present-at-the-44th-annual-association-for-research-in-otolaryngology-aro-conference\\\/\",\"name\":\"Decibel Therapeutics to Present at the 44th Annual Association for Research in Otolaryngology (ARO) Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/decibel-therapeutics-to-present-at-the-44th-annual-association-for-research-in-otolaryngology-aro-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/decibel-therapeutics-to-present-at-the-44th-annual-association-for-research-in-otolaryngology-aro-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE1NjAzMCMzOTg0OTg5IzIyMDU3NTM=\",\"datePublished\":\"2021-02-19T12:03:15+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/decibel-therapeutics-to-present-at-the-44th-annual-association-for-research-in-otolaryngology-aro-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/decibel-therapeutics-to-present-at-the-44th-annual-association-for-research-in-otolaryngology-aro-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/decibel-therapeutics-to-present-at-the-44th-annual-association-for-research-in-otolaryngology-aro-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE1NjAzMCMzOTg0OTg5IzIyMDU3NTM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE1NjAzMCMzOTg0OTg5IzIyMDU3NTM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/decibel-therapeutics-to-present-at-the-44th-annual-association-for-research-in-otolaryngology-aro-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Decibel Therapeutics to Present at the 44th Annual Association for Research in Otolaryngology (ARO) Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Decibel Therapeutics to Present at the 44th Annual Association for Research in Otolaryngology (ARO) Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/decibel-therapeutics-to-present-at-the-44th-annual-association-for-research-in-otolaryngology-aro-conference\/","og_locale":"en_US","og_type":"article","og_title":"Decibel Therapeutics to Present at the 44th Annual Association for Research in Otolaryngology (ARO) Conference - Market Newsdesk","og_description":"BOSTON, Feb. 19, 2021 (GLOBE NEWSWIRE) &#8212; Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, announced today that it will present findings from its drug discovery and development programs at the 44th Annual MidWinter Meeting of the Association for Research in Otolaryngology (ARO), which will be held virtually February 20\u201324, 2021. The Decibel team will have a total of eight podium and poster presentations during this year\u2019s meeting. Several presentations will focus on DB-OTO, Decibel\u2019s investigational gene therapy being developed to restore hearing in children with a deficiency in the otoferlin gene, and DB-ATO, a regenerative gene therapy program designed to restore balance in patients with &hellip; Continue reading \"Decibel Therapeutics to Present at the 44th Annual Association for Research in Otolaryngology (ARO) Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/decibel-therapeutics-to-present-at-the-44th-annual-association-for-research-in-otolaryngology-aro-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-02-19T12:03:15+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NjAzMCMzOTg0OTg5IzIyMDU3NTM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/decibel-therapeutics-to-present-at-the-44th-annual-association-for-research-in-otolaryngology-aro-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/decibel-therapeutics-to-present-at-the-44th-annual-association-for-research-in-otolaryngology-aro-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Decibel Therapeutics to Present at the 44th Annual Association for Research in Otolaryngology (ARO) Conference","datePublished":"2021-02-19T12:03:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/decibel-therapeutics-to-present-at-the-44th-annual-association-for-research-in-otolaryngology-aro-conference\/"},"wordCount":503,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/decibel-therapeutics-to-present-at-the-44th-annual-association-for-research-in-otolaryngology-aro-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NjAzMCMzOTg0OTg5IzIyMDU3NTM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/decibel-therapeutics-to-present-at-the-44th-annual-association-for-research-in-otolaryngology-aro-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/decibel-therapeutics-to-present-at-the-44th-annual-association-for-research-in-otolaryngology-aro-conference\/","name":"Decibel Therapeutics to Present at the 44th Annual Association for Research in Otolaryngology (ARO) Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/decibel-therapeutics-to-present-at-the-44th-annual-association-for-research-in-otolaryngology-aro-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/decibel-therapeutics-to-present-at-the-44th-annual-association-for-research-in-otolaryngology-aro-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NjAzMCMzOTg0OTg5IzIyMDU3NTM=","datePublished":"2021-02-19T12:03:15+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/decibel-therapeutics-to-present-at-the-44th-annual-association-for-research-in-otolaryngology-aro-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/decibel-therapeutics-to-present-at-the-44th-annual-association-for-research-in-otolaryngology-aro-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/decibel-therapeutics-to-present-at-the-44th-annual-association-for-research-in-otolaryngology-aro-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NjAzMCMzOTg0OTg5IzIyMDU3NTM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NjAzMCMzOTg0OTg5IzIyMDU3NTM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/decibel-therapeutics-to-present-at-the-44th-annual-association-for-research-in-otolaryngology-aro-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Decibel Therapeutics to Present at the 44th Annual Association for Research in Otolaryngology (ARO) Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/439741","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=439741"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/439741\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=439741"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=439741"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=439741"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}